- Immunologic monitoring in kidney transplant recipients
-
Townamchai N, Safa K, Chandraker A
- KMID: 2093108
- Kidney Res Clin Pract.
- 2013 Jun;32(2):52-61.
Transplant biopsy has always been the gold standard for assessing the immune response to a kidney allograft (Chandraker A: Diagnostic techniques in the work-up of renal allograft dysfunction-an update. Curr... -
- CITED
-
- Close
- SHARE
-
- Close
- Benefits of switching mycophenolic acid to sirolimus on serological response after a SARS-CoV-2 booster dose among kidney transplant recipients: a randomized controlled trial
-
Townamchai N, Banjongjit A, Phannajit J, Jantarabenjakul W, Paitoonpong L, Wattanatorn S, Avihingsanon Y, Hansasuta P, Vanichanan J, Eiam-Ong S
- KMID: 2535640
- Korean J Transplant.
- 2022 Nov;36(Supple 1):S124.
- doi: 10.4285/ATW2022.F-2423
Kidney transplant recipients (KTRs) have a suboptimal immune response to COVID-19 vaccination due to the effect of immu-nosuppression, mostly mycophenolic acid (MPA). This study was conducted to investigate the benefits... -
- CITED
-
- Close
- SHARE
-
- Close
- A noninferiority, randomized controlled trial of late conversion to once-daily regimen of sirolimus and extended-release tacrolimus versus mycophenolic acid and extended-release tacrolimus for kidney transplant recipients
-
Kitrungphaiboon T, Udomkarnjananan S, Kupatawintu P, Limbutara K, Iampenkhae K, Pongpirul K, Avihingsanon Y, Townamchai N
- KMID: 2535700
- Korean J Transplant.
- 2022 Nov;36(Supple 1):S184.
- doi: 10.4285/ATW2022.F-3114
Background: Once daily regimen could improve medical adherence and quality of life. Sirolimus based regimen can reduce calcineurin inhibitor (CNI) exposure. Therefore, we conducted randomized controlled trial, comparing once daily... -
- CITED
-
- Close
- SHARE
-
- Close
